The Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI-PGx) brings together academia, industry, regulators, and patients to accelerate the adoption of pharmacogenomics in the UK. Our aim is to develop guidelines, industry pathways, educational and training platforms, and assess the health economics of pharmacogenomics, ensuring patients benefit from innovative treatments.

• Our Mission
• Who We Are
• Regulatory Science and Pharmacogenomics Explained
• Funders and Stakeholders

Our mission

CERSI-PGx aims to catalyse innovative strategies for incorporating pharmacogenomics into UK regulatory pathways. By fostering collaboration across all four UK nations, we seek to position the UK at the forefront of pharmacogenomic advancements.

Who we are

Led by the University of Liverpool, CERSI-PGx partners with The University of Manchester, Queen Mary University of London, Bangor University, The Office of Health Economics, The British Pharmacological Society, JS O’Brien Business Solutions, and Alderley Lighthouse Labs.

Regulatory Science and Pharmacogenomics Explained

Regulatory science involves developing new tools, standards, and approaches to assess the safety, efficacy, and quality of medical products. Pharmacogenomics studies how genetic variation affects drug response, enhancing efficacy and safety.

Funders and Stakeholders

CERSI-PGx is funded by Innovate UK in partnership with the MHRA, Office for Life Sciences, and the Medical Research Council. Multiple regulatory bodies are consulted to ensure safe and effective implementation.